Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
14.85
-0.98 (-6.19%)
Jun 29, 2026, 11:31 AM EDT - Market open
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$2,363,785
Market Cap
2.24B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Immunome | 206 |
| Pharvaris | 134 |
| Kodiak Sciences | 130 |
BHVN News
- 1 hour ago - Biohaven falls -9.8% - TheFly
- 3 hours ago - Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease - TheFly
- 4 hours ago - Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease - PRNewsWire
- 5 hours ago - Biohaven downgraded to Underperform from Neutral at BofA - TheFly
- 3 days ago - Biohaven rises 7.4% - TheFly
- 3 days ago - Biohaven price target raised to $20 from $15 at Deutsche Bank - TheFly
- 4 weeks ago - Biohaven initiates first-in-human dosing for BHV-8100 - TheFly
- 4 weeks ago - Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation - PRNewsWire